StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen kYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
314
Period ended Jun 30, 2026
Change on a year earlier
-16.9%
378 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
31
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026314-16.9%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026330+1.9%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025351-5.6%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025359-5.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025378+0.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025324-13.8%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024372+6.3%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024378+8.3%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024377+9.0%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024376+5.0%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023350+7.7%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023349+9.7%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023346+9.1%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023358+24.7%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022325+14.4%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022318+8.5%Form 10-Q (filed 2023-10-31) ↗

Breakdown

What makes up kyprolis (carfilzomib — relapsed/refractory multiple myeloma) — worldwide product sales ($m)

Cite this data

StockData. (2026). Amgen KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M) ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_kyprolis_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.